New from Fresenius Kabi

The American Society for Parenteral and Enteral Nutrition (ASPEN) and Fresenius Kabi announced a new educational video series highlighting best practices for dosing, preparing and administering intravenous lipid emulsions (ILE). Designed for clinicians who provide nutrition support, the series address a knowledge gap between best practice recommendations and current practices in parenteral nutrition (PN).  "Lipids provide energy and essential fatty acids, and ASPEN's survey results demonstrate a need for a better understanding of ILE provision in current practice,"said Seema Kumbhat, M.D., senior vice president and regional medical director at Fresenius Kabi in North America. "This video series is designed to educate healthcare providers on ILE best practices, such that optimal nutrition can be delivered to patients who need it.'  For more on this series, click here.

Remifentanil Hydrochloride for Injection CII Now Available : First-to-Market Alternative to ULTIVA® "Fresenius Kabi has been investing significantly in product development over the last several years, and plans to launch multiple generic injectable products in the U.S. this year," said John Ducker, president and CEO of Fresenius Kabi USA.  For the press release, click here

Bortezomib for Injection: First available IV administration alternative to VELCADE® Bortezomib for Injection for intravenous use is indicated for the treatment of patients with multiple myeloma and for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.  Tor the press release, click here.